Lilly's Prices After Concessions Rise 6% In 2017, While Merck's Net Prices Decline
Price transparency reports from the big pharmas also show continued increases in price concessions in 2017, but a slow-down in list price increases.
You may also be interested in...
Insurer suggests manufacturers may not be willing to lower list prices enough to make up financial shortfalls in Medicare Part D that would be caused by restrictions on rebates.
Transparency reports from companies aim to change conversation from prices to discounts, but also invite comparisons. Lilly, for example, saw a higher average list price increase in 2016 than Merck and Janssen, but its net prices grew by less than the others.
Eli Lilly recorded $7.69bn in rebates and discounts in the US in 2016 as pharmacy benefit managers demanded greater price concessions in crowded categories like diabetes.